PE20030604A1 - Tetrahidroquinolinas - Google Patents

Tetrahidroquinolinas

Info

Publication number
PE20030604A1
PE20030604A1 PE2002000962A PE2002000962A PE20030604A1 PE 20030604 A1 PE20030604 A1 PE 20030604A1 PE 2002000962 A PE2002000962 A PE 2002000962A PE 2002000962 A PE2002000962 A PE 2002000962A PE 20030604 A1 PE20030604 A1 PE 20030604A1
Authority
PE
Peru
Prior art keywords
isopropyl
refers
tetrahydroquinolines
trifluoromethylphenil
fluorophenil
Prior art date
Application number
PE2002000962A
Other languages
English (en)
Spanish (es)
Inventor
Hilmar Bischoff
Christiane Faeste
Heiken Gielen
Siegfried Goldmann
Stephan Siegel
Holger Paulsen
Martin Raabe
Carsten Schmeck
Delf Schmidt
Jorg Keldenich
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of PE20030604A1 publication Critical patent/PE20030604A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
PE2002000962A 2001-10-01 2002-09-30 Tetrahidroquinolinas PE20030604A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10148436A DE10148436A1 (de) 2001-10-01 2001-10-01 Tetrahydrochinoline

Publications (1)

Publication Number Publication Date
PE20030604A1 true PE20030604A1 (es) 2003-09-07

Family

ID=7701007

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000962A PE20030604A1 (es) 2001-10-01 2002-09-30 Tetrahidroquinolinas

Country Status (12)

Country Link
US (1) US20050043341A1 (enExample)
EP (1) EP1434581A1 (enExample)
JP (1) JP2005508341A (enExample)
AR (1) AR036583A1 (enExample)
CA (1) CA2462030A1 (enExample)
DE (1) DE10148436A1 (enExample)
DO (1) DOP2002000457A (enExample)
GT (1) GT200200195A (enExample)
HN (1) HN2002000278A (enExample)
PE (1) PE20030604A1 (enExample)
UY (1) UY27458A1 (enExample)
WO (1) WO2003028727A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070087197A (ko) 2003-09-26 2007-08-27 니뽄 다바코 산교 가부시키가이샤 잔여 리포프로테인 생산 저해 방법
WO2005037796A1 (en) 2003-10-08 2005-04-28 Eli Lilly And Company Compounds and methods for treating dyslipidemia
BRPI0508966A (pt) 2004-03-26 2007-08-21 Lilly Co Eli composto, composição farmacêutica, e, uso de um composto
MX2007007188A (es) * 2004-12-18 2007-08-14 Bayer Healthcare Ag Derivados de tetrahidroquinolina sustituidos en 4 con cicloalquilo y su uso como medicamentos.
EP1828136A1 (de) * 2004-12-18 2007-09-05 Bayer HealthCare AG (5s)-3-[(s)-fluor(4-trifluoromethylphenyl)methyl]-5,6,7,8-tetrahydrochinolin-5-ol derivate und ihre verwendung als cetp-inhibitoren
DE102006012548A1 (de) 2006-03-18 2007-09-20 Bayer Healthcare Ag Substituierte Chromanol-Derivate und ihre Verwendung
CN101096363B (zh) * 2006-06-27 2011-05-11 中国人民解放军军事医学科学院毒物药物研究所 2,4,5-三取代噻唑类化合物、其制备方法、药物组合物及其制药用途
US20080145498A1 (en) * 2006-12-14 2008-06-19 Kraft Foods Holdings, Inc. Texture and shape control process for acidified food products
AU2009221179A1 (en) * 2008-03-05 2009-09-11 Boehringer Ingelheim International Gmbh Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
AU2011217206A1 (en) 2010-02-19 2012-08-02 Boehringer Ingelheim International Gmbh Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
MX2013000359A (es) 2010-07-09 2013-02-11 Ube Industries Compuesto de piridina sustituida.
EP2760868B1 (en) 2011-08-17 2018-04-25 Boehringer Ingelheim International GmbH Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation
CA2860601C (en) 2012-01-06 2016-07-05 Daiichi Sankyo Company, Limited Acid addition salt of substituted pyridine compound
US9938228B2 (en) 2014-09-09 2018-04-10 Boehringer Ingelheim International Gmbh Process for the preparation of spiro[2.5]octane-5,7-dione and spiro[3.5]nonane-6,8-dione

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP970330B1 (en) * 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
MA24643A1 (fr) * 1997-09-18 1999-04-01 Bayer Ag Tetrahydro-naphtalenes substitues et composes analogues
DE19741051A1 (de) * 1997-09-18 1999-03-25 Bayer Ag Hetero-Tetrahydrochinoline
DE19741399A1 (de) * 1997-09-19 1999-03-25 Bayer Ag Tetrahydrochinoline

Also Published As

Publication number Publication date
GT200200195A (es) 2003-08-22
WO2003028727A1 (de) 2003-04-10
JP2005508341A (ja) 2005-03-31
DOP2002000457A (es) 2003-04-15
HN2002000278A (es) 2002-12-20
US20050043341A1 (en) 2005-02-24
CA2462030A1 (en) 2003-04-10
UY27458A1 (es) 2003-04-30
WO2003028727A9 (de) 2003-11-13
AR036583A1 (es) 2004-09-15
DE10148436A1 (de) 2003-04-17
EP1434581A1 (de) 2004-07-07

Similar Documents

Publication Publication Date Title
NO981628L (no) (Metylsulfonyl)fenyl-2-(5H)-furanoner som cox-2 inhibitorer
CR7743A (es) Nuevos compuestos de oxazol y tiazol como inhibidorea del factor de crecimiento transformador (tgf)
BRPI0417684A (pt) composto, composição farmacêutica, e, uso de um composto
ES2115237T3 (es) Fenil heterociclos como inhibidores de la ciclooxigenasa-2.
BRPI0418251B8 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
EA200300171A1 (ru) Циклопентаноиндолы, композиции, содержащие данные соединения, и способы лечения
CY1110914T1 (el) Δικυκλο-πυραζολες δραστικες ως αναστολεις kinασων, διεργασια για την παρασκευη τους και φαρμακευτικες συνθεσεις που τις περιλαμβανουν
PE20020722A1 (es) Derivados de glucopiranosiloxipirazol como inhibidor del sglt2 humano
UY26130A1 (es) Compuestos para tratar la obesidad
SE0101387D0 (sv) Novel compounds
BG66080B1 (bg) Заместени тиоацетамиди
EA200500286A1 (ru) Новые изотиазольные и изоксазольные соединения в качестве ингибиторов трансформирующего фактора роста (тфр)
UY27981A1 (es) Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf)
ES2171723T3 (es) 3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2.
AR021843A1 (es) Derivados de propanolamina sustituidos con heterociclos, procedimiento para su preparacion, y su utilizacion.
PT1401415E (pt) Utilizacao de derivados de n-fenil-2-pirimidino-amina para o tratamento de doencas inflamatorias
ATE332302T1 (de) Alkylierte imidazopyridinderivate
ATE369348T1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
ATE223376T1 (de) Bisarylcyclobutenderivate als cyclooxygenasehemmer
UY26895A1 (es) Compuestos de pirazol, composiciones farmacéuticas, y métodos para modular y/o inhibir la actividad de erab/hadh2
DE69702182D1 (de) Alkylierte styrole als prodrugs zu cox-2-inhibitoren
DE69819539D1 (de) Antithrombotische mittel
ATE335739T1 (de) Cak inhibitoren und deren verwendungen
ATE301933T1 (de) Akarizidpulver
TW200718423A (en) Heteroatom-interrupted analogs of 15-hydroxyeicosatetraenoic acid and pharmaceutical composition thereof

Legal Events

Date Code Title Description
FD Application declared void or lapsed